Recurrent Wnt Pathway and ARID1A Alterations in Sinonasal Olfactory Carcinoma.

Nasal neoplasms adenocarcinoma immunohistochemistry molecular diagnostics neuroendocrine carcinoma olfactory carcinoma olfactory neuroblastoma teratocarcinosarcoma

Journal

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605

Informations de publication

Date de publication:
16 Feb 2024
Historique:
received: 28 05 2023
revised: 04 02 2024
accepted: 06 02 2024
medline: 19 2 2024
pubmed: 19 2 2024
entrez: 18 2 2024
Statut: aheadofprint

Résumé

Sinonasal tumors with neuroepithelial differentiation, defined by neuroectodermal elements reminiscent of olfactory neuroblastoma (ONB) and epithelial features such as keratin expression or gland formation, are a diagnostically challenging group that have never formally been included in sinonasal tumor classifications. Recently, we documented that most of these neuroepithelial neoplasms have distinctive histologic and immunohistochemical findings and proposed the term olfactory carcinoma to describe these tumors. However, the molecular characteristics of olfactory carcinoma have not yet been evaluated. In this study, we performed targeted molecular profiling of 23 sinonasal olfactory carcinoma to further clarify their pathogenesis and classification. All tumors included in this study were composed of high-grade neuroectodermal cells that were positive for pankeratin and at least one specific neuroendocrine marker. A significant subset of cases also displayed rosettes and neurofibrillary matrix, intermixed glands with variable cilia, peripheral p63/p40 expression, and S100 protein-positive sustentacular cells. Recurrent oncogenic molecular alterations were identified in 20 tumors, including Wnt pathway alterations affecting CTNNB1 (n=8) and PPP2R1A (n=2), ARID1A inactivation (n=5), RUNX1 mutations (n=3), and IDH2 hotspot mutations (n=2). Overall, these findings do demonstrate the presence of recurrent molecular alterations in olfactory carcinoma, although this group of tumors does not appear to be defined by any single mutation. Minimal overlap with alterations previously reported in ONB also adds to histologic and immunohistochemical separation between ONB and olfactory carcinoma. Conversely, these molecular findings enhance overlap between olfactory carcinoma and sinonasal neuroendocrine carcinoma. A small subset of neuroepithelial tumors might better fit into the superseding molecular category of IDH2-mutant sinonasal carcinoma. At this point, sinonasal neuroendocrine and neuroepithelial tumors may best be regarded as a histologic and molecular spectrum that includes core groups of ONB, olfactory carcinoma, neuroendocrine carcinoma, and IDH2-mutant sinonasal carcinoma.

Identifiants

pubmed: 38369189
pii: S0893-3952(24)00028-0
doi: 10.1016/j.modpat.2024.100448
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100448

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Lisa M Rooper (LM)

Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: rooper@jhmi.edu.

Abbas Agaimy (A)

Institute of Pathology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital, Erlangen, Germany.

Diana Bell (D)

Department of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

Jeffrey Gagan (J)

Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Gary L Gallia (GL)

Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Vickie Y Jo (VY)

Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

James S Lewis (JS)

Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Otolaryngology - Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.

Nyall R London (NR)

Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Michiya Nishino (M)

Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.

Robert Stoehr (R)

Institute of Pathology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital, Erlangen, Germany.

Lester D R Thompson (LDR)

Head and Neck Pathology Consultations, Woodland Hills, CA, USA.

Nasir Ud Din (NU)

Department of Pathology and Laboratory Medicine, Aga Khan University, Karachi, Pakistan.

Bruce M Wenig (BM)

Department of Pathology, Moffitt Cancer Center, Tampa, FL, USA.

William H Westra (WH)

Department of Pathology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.

Justin A Bishop (JA)

Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Classifications MeSH